Background: BR. 21 is a double-blind, placebo-controlled trial of second-/third-line erlotinib
in stage IIIB/IV non-small cell lung cancer patients. Predictive and prognostic analyses of …

Objectives Epidermal growth factor receptor (EGFR) mutations are important predictors of
treatment response to tyrosine kinase inhibitors (TKIs) in patients with non− small cell lung …

Background Patients with advanced-stage non–small cell lung cancer with epidermal
growth factor receptor (EGFR) mutations are successfully treated with tyrosine kinase …

Within the past 2 years, epidermal growth factor receptor (EGFR) inhibitors have moved from
experimental agents to approved drugs for the management of advanced non–small cell …

Background The TORCH phase III trial compared the efficacy of first-line erlotinib followed
by chemotherapy at progression (experimental arm) with the reverse sequence (standard …

Objectives Somatic mutations in the epidermal growth factor receptor (EGFR) are predictors
of efficacy for treatment with the EGFR tyrosine kinase inhibitor erlotinib in non-small cell …

The efficacy of erlotinib treatment for advanced non-small cell lung cancer (NSCLC) is due
to its action as an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) …

Purpose: This study investigated possible molecular predictors of outcome in Korean
patients with advanced non-small cell lung cancer treated with erlotinib. Experimental …

Background Identification of appropriate markers for predicting clinical benefit with erlotinib
in non-small-cell lung cancer (NSCLC) may be able to guide patient selection for treatment …

7522 Background: When EGFR compound mutants (exon 19 deletions or L858R
plusT790M) are present at the time of clinical resistance to erlotinib, patients attain longer …